TY - JOUR T1 - Single-cell analysis of bronchoalveolar cells in inflammatory and fibrotic post-COVID lung disease JF - medRxiv DO - 10.1101/2023.03.28.23287759 SP - 2023.03.28.23287759 AU - Puja Mehta AU - Blanca Sanz-Magallón Duque de Estrada AU - Emma K Denneny AU - Kane Foster AU - Carolin T Turner AU - Andreas Mayer AU - Martina Milighetti AU - Manuela Platé AU - Kaylee B Worlock AU - Masahiro Yoshida AU - Jeremy S Brown AU - Marko Z Nikolić AU - Arjun Nair AU - Benjamin M Chain AU - Mahdad Noursadeghi AU - Rachel C Chambers AU - Joanna C Porter AU - Gillian S Tomlinson Y1 - 2023/01/01 UR - http://medrxiv.org/content/early/2023/03/29/2023.03.28.23287759.abstract N2 - Rationale Persistent pulmonary sequelae are evident in many survivors of acute coronavirus disease 2019 (COVID-19) but the molecular mechanisms responsible are incompletely understood. Post-COVID radiological lung abnormalities comprise two broad categories, organising pneumonia and reticulation, interpreted as indicative of subacute inflammation and fibrosis, respectively. Whether these two patterns represent distinct pathologies, likely to require different treatment strategies is not known.Objectives We sought to identify differences at molecular and cellular level, in the local immunopathology of post-COVID inflammation and fibrosis.Methods We compared single-cell transcriptomic profiles and T cell receptor (TCR) repertoires of bronchoalveolar cells obtained from convalescent individuals with each radiological pattern of post-COVID lung disease (PCLD).Measurements and Main Results Inflammatory and fibrotic PCLD single-cell transcriptomes closely resembled each other across all cell types. However, CD4 central memory T cells (TCM) and CD8 effector memory T cells (TEM) were significantly more abundant in inflammatory PCLD. A greater proportion of CD4 TCM also exhibited clonal expansion in inflammatory PCLD. High levels of clustering of similar TCRs from multiple donors was a striking feature of both PCLD phenotypes, consistent with tissue localised antigen-specific immune responses, but there was no enrichment for known SARS-CoV-2 reactive TCRs.Conclusions There is no evidence that radiographic organising pneumonia and reticulation in PCLD are associated with differential immmunopathological pathways. Inflammatory radiology is characterised by greater bronchoalveolar T cell accumulation. Both groups show evidence of shared antigen-specific T cell responses, but the antigenic target for these T cells remains to be identified.Scientific knowledge on the subject The immune pathogenesis of persistent pulmonary radiological abnormalities following COVID-19 is poorly understood. Whether post-COVID radiological inflammation and fibrosis represent distinct disease entities with different molecular mechanisms of tissue injury is not known.What this study adds to the field Single-cell bronchoalveolar transcriptomes of inflammatory and fibrotic post-COVID lung disease closely resemble each other across all cell types, but CD4 central memory and CD8 effector memory T cells are more abundant in the inflammatory group. Marked T cell receptor clustering, suggestive of antigen-specific responses is evident in both phenotypes. These two radiological patterns likely represent different manifestations of the same disease process, which may benefit from therapies which target T cells.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPM is supported by a Medical Research Council (MRC)/GlaxoSmithKline Experimental Medicine Initiative to Explore New Therapies network (EMINENT) Clinical Research Training Fellowship. EKD is supported by Breathing Matters. MZN is supported by a UK MRC Clinician Scientist Fellowship (MR/W00111X/1) and a Rutherford Fund Fellowship allocated by the MRC UK Regenerative Medicine Platform 2 (MR/5005579/1). MN is supported by the Wellcome Trust (207511/Z/17/Z). GST is supported by a UK MRC Clinician Scientist Fellowship (MR/N007727/1). PM, EKD, MP, JSB, MZN, MN, RCC, JCP and GST are also supported by NIHR Biomedical Research Funding to UCL and UCLH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by a UK Research Ethics Committee (North London Research Ethics Committee, reference 13/LO/0900). Written informed consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesscRNAseq and scTCRseq data will be available in the Gene Expression Omnibus (GEO) database at the time of peer-reviewed publication of the manuscript. ER -